# US 2021/0228660 A1 · Use of proteasome inhibitor and alphavirus in preparation of anti-tumor medicament

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0228660 A1
- Document ID: US20210228660A1
- Status: Published application
- Kind: A1
- Application number: 17/057,489
- Filed: 2019-05-22
- Published: 2021-07-29
- Earliest claimed: 2018-05-22
- Assignees: Guangzhou Virotech Pharmaceutical Co., Ltd.
- Applicants: Guangzhou Virotech Pharmaceutical Co., Ltd.
- Inventors: Guangmei YAN; Haipeng ZHANG; Wenbo ZHU; Yuan LIN; Shoufang GONG; Jiankai LIANG; Jing CAI; Chunqiang LIU
- Web page: https://patentgrep.com/patent/US20210228660A1

## CPC

- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/69: Boron compounds
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 38/05: Dipeptides
- A61K 38/07: Tetrapeptides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 2770/36132: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Use of a proteasome inhibitor and an alphavirus in the preparation of an anti-tumor medicament. The proteasome inhibitor can be used to prepare an alphavirus anti-tumor synergist. A pharmaceutical composition comprising a proteasome inhibitor and an alphavirus, including a pharmaceutical kit comprising the proteasome inhibitor and the alphavirus, and use of the proteasome inhibitor and the virus in the treatment of tumors, particularly tumors insensitive to the alphavirus.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A method for treating a tumor in a subject in need thereof, comprising:
administering to the subject in need thereof
an effective amount of a proteasome inhibitor, and
an effective amount of an alphavirus.

### Claim 12 (depends on 11)

The method of claim 11, wherein the alphavirus is selected from the group consisting of Eastern Equine Encephalitis virus, Venezuelan Equine Encephalitis virus, Everglades virus, Mucambo virus, Pixuna virus, Western Encephalitis virus, Sindbis virus, South African arbovirus No. 86, Girdwood S. A. virus, Ockelbo virus, Semliki Forest virus, Middleburg virus, Chikungunya virus, O'Nyong-Nyong virus, Ross River virus, Barmah Forest virus, Sagiyama virus, Bebaru virus, Mayaro virus, Una virus, Aura virus, Whataroa virus, Babanki virus, Kyzlagach virus, Highlands J virus, Fort Morgan virus, Ndumu virus, Buggy Creek virus, M1 virus and Getah virus.

### Claim 13 (depends on 11)

The method of claim 11, wherein the alphavirus is selected from at least one of M1 virus and Getah virus.

### Claim 14 (depends on 11)

The method of claim 11, wherein the alphavirus is M1 virus.

### Claim 15 (depends on 11)

The method of claim 11, wherein
the genome sequence of the alphavirus has at least 95% identity to the sequence indicated by Genbank Accession No. EF011023; and/or
the genome sequence of the alphavirus has at least 95% identity to the genome sequence of the virus deposited under accession No. CCTCC V201423.

### Claim 16 (depends on 11)

The method of claim 11, wherein the proteasome inhibitor is a substance that inhibits proteasome activity, or inhibits the activity or expression of any one subunit of the proteasome, or blocks assembly of proteasome subunits, or degrades the proteasome.

### Claim 17 (depends on 11)

The method of claim 11, wherein the proteasome inhibitor is selected from a group consisting of:
Bortezomib, Carfilzomib, MG-132, ONX-0914, ONX-0912, CEP-18770, MLN-9708, Epoxomicin, VR23, MLN-2238, Celastrol and P1-18400;
or derivatives thereof having proteasome inhibitory effect, or pharmaceutically acceptable salts, solvates, tautomers, isomers thereof.

### Claim 18 (depends on 11)

The method of claim 11, wherein the proteasome inhibitor is selected from a group consisting of:
Bortezomib, Carfilzomib, MG-132, ONX-0914, ONX-0912, CEP-18770 and MLN-9708;
or derivatives thereof having proteasome inhibitory effect, or pharmaceutically acceptable salts, solvates, tautomers, isomers thereof.

### Claim 19 (depends on 11)

The method of claim 11, wherein the proteasome inhibitor is selected from gene interference, gene editing, gene silencing or gene knockout materials.

### Claim 20 (depends on 11)

The method of claim 11, wherein the proteasome inhibitor is selected from one or more of DNA, RNA, PNA and DNA-RNA hybrids.

### Claim 21 (depends on 11)

The method of claim 11, wherein the proteasome inhibitor is selected from one or more of siRNA, dsRNA, miRNA, shRNA and ribozyme.

### Claim 22 (depends on 11)

The method of claim 11, wherein the proteasome inhibitor is a tumor targeting proteasome inhibitor.

### Claim 23 (depends on 11)

The method of claim 11, wherein the tumor is a solid tumor or a hematological tumor.

### Claim 24 (depends on 11)

The method of claim 11, wherein the tumor is selected from a group consisting of:
adrenocortical carcinoma, pararenocortical carcinoma, anal carcinoma, appendiceal carcinoma, astrocytoma, atypical teratoma, rhabdomyoma, basal cell carcinoma, cholangiocarcinoma, bladder cancer, bone cancer, brain tumor, bronchial tumor, Burkett's lymphoma, carcinoid tumor, heart tumor, bile duct epithelial carcinoma, chordoma, colorectal cancer, craniopharyngioma, ductal carcinoma in situ, embryonal tumor, endometrial carcinoma, ependymoma, esophageal carcinoma, olfactory neuroblastoma, intracranial embryonic cell tumor, extragonadal germ cell tumor, eye cancer, carcinoma of the fallopian tube, gallbladder carcinoma, head and neck cancer, hypopharyngeal carcinoma, Kaposi's sarcoma, renal carcinoma, Langerhans cell histiocytosis, laryngeal carcinoma, lip cancer, oral cancer, Meckel cell carcinoma, malignant mesothelioma, multiple endocrine neoplasia syndrome, mycosis fungoides, nasal sinus carcinoma, neuroblastoma, non-small cell lung cancer, ovarian cancer, pancreatic neuroendocrine tumor, islet cell tumor, papillomatosis, paraganglioma, carcinoma of nasal sinus and nasal cavity, parathyroid carcinoma, carcinoma of penis, carcinoma of pharynx and larynx, pituitary tumor, pleuropulmonary blastoma, primary peritoneal carcinoma, retinoblastoma, salivary gland tumor, sarcoma, Sézary syndrome, skin cancer, small cell lung cancer, small intestinal carcinoma, soft tissue sarcoma, squamous cell carcinoma, testicular cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, endometrium and uterine sarcoma, vaginal carcinoma, vascular tumor, vulvar carcinoma, solitary myeloma, liver cancer, colorectal cancer, bladder cancer, breast cancer, cervical cancer, prostate cancer, glioma, melanoma, pancreatic cancer, nasopharyngeal cancer, lung cancer and gastric cancer.

### Claim 25 (depends on 11)

The method of claim 11, wherein the tumor is selected from a group consisting of:
liver cancer, colorectal cancer, bladder cancer, breast cancer, cervical cancer, prostate cancer, glioma, melanoma, pancreatic cancer, nasopharyngeal cancer, lung cancer and gastric cancer.

### Claim 26 (depends on 11)

The method of claim 11, wherein the tumor is selected from a group consisting of:
acute lymphoblastic leukemia, acute myelocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, lymphoma or multiple myeloma.

### Claim 27 (depends on 11)

The method of claim 11, wherein the tumor is insensitive to alphavirus.

### Claim 28 (depends on 11)

The method of claim 11, wherein the ratio of said proteasome inhibitor and said alphavirus is 0.01 to 200 mg: 103 to 109 PFU.

### Claim 29 (depends on 11)

The method of claim 11, wherein
0.01 mg/kg to 200 mg/kg of said proteasome inhibitor is administered; and
a titer at MOI from 103 to 109 PFU/kg of said alphavirus is administered.

### Claim 30 (depends on 11)

The method of claim 11, wherein
said proteasome inhibitor is administered intraperitoneally, intravenously, intra-arterially, intramuscularly, intradermally, intratumorally, subcutaneously or intranasally; and/or
said alphavirus is administered intraperitoneally, intravenously, intra-arterially, intramuscularly, intradermally, intratumorally, subcutaneously or intranasally.
